Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 12/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082839 | 0.88 | TNK2 (0.41) | TNK2LMNAL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5086596 | 0.88 | TNK2 (0.42) | TNK2IGF1RCYP3A4LMNAL3MBTL1 | |
| SCHEMBL5083969 | 0.87 | IGF1R (0.46) | TNK2IGF1RCYP3A4EGFR | |
| SCHEMBL5081269 | 0.85 | CYP3A4 (0.39) | TNK2IGF1RCYP3A4KDM4EALDH1A1 | |
| SCHEMBL5082157 | 0.81 | IGF1R (0.38) | TNK2IGF1RCYP3A4MCHR1 | |
| SCHEMBL5258044 | 0.80 | IGF1R (0.58) | TNK2IGF1RCYP3A4EGFR | |
| SCHEMBL5078897 | 0.77 | TNK2 (0.40) | TNK2IGF1RCYP3A4 | |
| SCHEMBL400519 | 0.75 | TNK2 (0.74) | TNK2IGF1RCYP3A4 | |
| SCHEMBL5083250 | 0.74 | TNK2 (0.45) | TNK2IGF1R | |
| SCHEMBL5082928 | 0.74 | IGF1R (0.40) | TNK2IGF1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |